Probiotics and Antimicrobial Proteins, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 12, 2024
Language: Английский
Biotechnology Advances, Journal Year: 2024, Volume and Issue: 72, P. 108336 - 108336
Published: March 2, 2024
Language: Английский
Citations
31
Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(3), P. 382 - 395.e10
Published: Feb. 2, 2024
Methionine is an essential proteinogenic amino acid, but its excess can lead to deleterious effects. Inborn errors of methionine metabolism resulting from loss function in cystathionine β-synthase (CBS) cause classic homocystinuria (HCU), which managed by a methionine-restricted diet. Synthetic biotics are gastrointestinal tract-targeted live biotherapeutics that be engineered replicate the benefits dietary restriction. In this study, we assess whether SYNB1353, E. coli Nissle 1917 derivative, impacts circulating and homocysteine levels animals healthy volunteers. both mice nonhuman primates (NHPs), SYNB1353 blunts appearance plasma response oral load. A phase 1 clinical study conducted volunteers subjected challenge demonstrates well tolerated 26%. Overall, represents promising approach for reduction with potential utility treatment HCU.
Language: Английский
Citations
18
Matter, Journal Year: 2024, Volume and Issue: 7(4), P. 1440 - 1465
Published: Feb. 26, 2024
Language: Английский
Citations
11
Gut, Journal Year: 2025, Volume and Issue: unknown, P. gutjnl - 334501
Published: Feb. 26, 2025
Objective Live biotherapeutic products (LBPs) are biological composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains Akkermansia muciniphila and Christensenella minuta , as well treatments using purified Firmicutes spores for recurrent Clostridioides difficile infections. There is a need guidelines over the increasing interest in developing LBPs. A panel microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations LBP development. Design Experts research, microbiology, gastroenterology, internal medicine biotherapeutics industry were invited form panel. During 2023 Inauguration Conference Microbiota Consortium, an organised, iterative roundtable discussion was conducted build expert consensus critical issues surrounding development LBP. Results The statements organised into three main aspects: (a) rationales development, (b) preclinical studies (c) preparation clinical studies. strongly recommended prioritise human-derived food-sourced with indications based efficacy shown Preclinical evaluation should involve thorough screening, genotyping phenotyping, comprehensive vitro animal assess functional mechanisms microbiological safety. Rigorous cell banking practices genetic monitoring essential ensure product consistency safety throughout manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed closely monitored, robust risk management protocols place. Conclusions approached strong emphasis evaluation, relevance, scientific at every stage. These measures safety, effectiveness long-term success product.
Language: Английский
Citations
1
Processes, Journal Year: 2024, Volume and Issue: 12(2), P. 316 - 316
Published: Feb. 2, 2024
Probiotics, living microorganisms with demonstrated health benefits when administered in sufficient quantities, have a rich history as dietary supplements to benefit human health. Recently, understanding of their mechanisms the gastrointestinal tract has prompted exploration probiotics treating diseases. However, effective and precise delivery remains significant challenge therapeutic applications. Here, we review action most advanced strategies for efficient probiotic delivery. We also discuss potential applications engineered disease treatment. This contributes insights into evolving landscape research
Language: Английский
Citations
8
Advanced Science, Journal Year: 2024, Volume and Issue: 11(15)
Published: Feb. 13, 2024
Abstract Phenylketonuria (PKU) is the most common inherited metabolic disease in humans. Clinical screening of newborn heel blood samples for PKU costly and time‐consuming because it requires multiple procedures, like isotope labeling derivatization, subtype identification an additional urine sample. Delayed diagnosis PKU, or can result mental disability. Here, plasmonic silver nanoshells are used laser desorption/ionization mass spectrometry (MS) detection with label‐free assay by recognizing profile dried spot (DBS) samples. A total 1100 subjects recruited each DBS sample be processed seconds. This platform achieves a sensitivity 0.985 specificity 0.995, which comparable to existing clinical liquid chromatography MS (LC‐MS) methods. method process 360 per hour, compared LC‐MS processes only 30 hour. Moreover, this enables precise subtypes without need It demonstrated that high‐performance fast, low‐cost identification. approach might suitable other clinically relevant biomarkers
Language: Английский
Citations
7
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Aug. 9, 2024
Influenza virus infection remains a major global health problem and requires universal vaccine with broad protection against different subtypes as well rapid-response to provide immediate in the event of an epidemic outbreak. Here, we show that intranasal administration probiotic Escherichia coli Nissle 1917 activates innate immunity respiratory tract provides influenza within 1 day. Based on this vehicle, recombinant strain is engineered express secret five tandem repeats extracellular domain matrix protein 2 from subtypes. Intranasal vaccination induces durable humoral mucosal responses tract, lethal challenge divergent viruses female BALB/c mice. Our findings highlight promising delivery platform for developing vaccines sustained pathogens.
Language: Английский
Citations
7
Nature Reviews Bioengineering, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 17, 2024
Language: Английский
Citations
7
Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: unknown
Published: May 1, 2024
The rising prevalence of metabolic diseases calls for innovative treatments. Peptide-based drugs have transformed the management conditions such as obesity and type 2 diabetes. Yet, challenges persist in oral delivery these peptides. This review explores potential 'advanced microbiome therapeutics' (AMTs), which involve engineered microbes peptides situ, thereby enhancing their bioavailability. Preclinical work on AMTs has shown promise treating animal models diseases, including obesity, diabetes, dysfunction-associated steatotic liver disease. Outstanding toward realizing improving peptide expression, ensuring predictable colonization control, stability, managing safety biocontainment concerns. Still, revolutionizing treatment potentially offering dynamic personalized novel therapeutic approaches.
Language: Английский
Citations
6
Trends in biotechnology, Journal Year: 2024, Volume and Issue: unknown
Published: July 1, 2024
Recent advances in engineered bacterial therapeutics underscore their potential treating diseases via targeted, live interventions. Despite promising performance early clinical phases, no therapeutic bacteria have yet received approval, primarily due to challenges proving efficacy while ensuring biosafety. Material science innovations, particularly the encapsulation of within hydrogels, present a avenue enhance survival, efficacy, and safety applications. This review discusses this interdisciplinary approach develop living materials. Hydrogels not only safeguard from harsh physiological conditions but also enable controlled release prevent unintended dissemination. The strategic use materials could redefine delivery functionality therapeutics, facilitating translation.
Language: Английский
Citations
5